The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The study will assess the safety and efficacy of Everolimus (RAD001) alone or in combination
with Lucentis in patients with neo-vascular age related macular degeneration (AMD)